WO2003000155A2 - Compositions and methods for reducing blood and fluid loss from open wounds - Google Patents
Compositions and methods for reducing blood and fluid loss from open wounds Download PDFInfo
- Publication number
- WO2003000155A2 WO2003000155A2 PCT/US2002/019554 US0219554W WO03000155A2 WO 2003000155 A2 WO2003000155 A2 WO 2003000155A2 US 0219554 W US0219554 W US 0219554W WO 03000155 A2 WO03000155 A2 WO 03000155A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- polyacrylic acid
- ofclaim
- gel
- structural formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0052—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Definitions
- This invention comprises a new method of use, and physiologically and medically acceptable compositions of matter having relatively low-cost; these provide hemorrhage and injury control comprising artificial clotting of blood, protective sealing of body surfaces with normal, damaged or destroyed skin, and temporary adhesion to or between such body surfaces.
- This invention further comprises new and useful compositions of matter, and applications thereof that use water, as found in blood and other body fluids, to activate the formation of artificial clots that can adhere to wounded tissue for the suppression of fluid loss and/or the protection of viable cells.
- Relatively minor injuries such as a superficially cut finger or scraped knee
- sterile cotton gauze pads that are held over the injured site by pressure from an adhesive barrier strip affixed to adjacent normal skin.
- Such first aid strips may be used to sequester small amounts of blood within the absorbent pad until components of blood and damaged tissue can form a fibrin-based clot.
- the clot initially clogs the ends of small blood vessels and adheres to wounded surfaces.
- the rapid flow of escaping blood tends to remove fibrin clots before they can clog the vessel and adhere to the adjacent damaged tissue. There is a requirement for material able to arrest such major hemorrhage.
- each an anticholinesterase "nerve agent” vesicants such as HD (bis-2-chloroethyl sulfide) and its close relative that is known as sesquimustard, "tear gas” irritant/vesicants such as CS (o-chlorobenzylidene malononitri ⁇ e) and CN (chloracetophenone), and various psychotomimietics such as BZ and EA3580 (anticholinergic agent prototypes).
- ve agent vesicants such as HD (bis-2-chloroethyl sulfide) and its close relative that is known as sesquimustard
- CS o-chlorobenzylidene malononitri ⁇ e
- CN chloracetophenone
- various psychotomimietics such as BZ and EA3580 (anticholinergic agent prototypes).
- BZ and EA3580 anticholinergic agent prototypes
- ointments or creams were developed to shield skin from contamination with toxic chemical warfare agents.
- Some of these protectants incorporated detoxifying components, thickeners, and camouflage pigments (example: M-5 ointment).
- tissue glues react with very thin layers of water on normal skin or wounded tissue surfaces that can be placed in apposition.
- none of these adhesives is compatible with substantial amounts or depths of water or blood on a body surface. None are useful as soft tissue splints that stabilize torn tissue in the manner of bone fragment stabilization with splints.
- lipophilic adhesives and pharmaceutical vehicles adhere poorly to wet surfaces of wounds. They tend to retain lipophilic drugs (for example, vitamins A, D, and E that are known to promote wound healing) rather than facilitate their distribution into wounded tissue. In contrast, lipophilic materials readily tend to leave hydrophilic materials to enter lipophilic tissue membranes.
- compositions comprising anhydrous polymers such as polyacrylic acids of various chain lengths and modified monomer components.
- polyacrylic acids of various chain lengths and modified monomer components.
- carbomers or carboxypolymethylenes have been identified by trade names such as Carbopol or Noveon.
- carbomers or carboxypolymethylenes have been identified by trade names such as Carbopol or Noveon.
- carbomers 934 P NF has allyl sucrose cross-links; it is designated P for pharmaceutical grade and NF for listing in the National Formulary.
- Differing cross-links, molecular weight, and/or concentration in water support differing degrees of carbomer swelling in water. Such features can be varied to optimize properties for typical usage in medical and personal use products for which thickening, dispersion, emulsification, or suspension of solid ingredients may be desired.
- Product viscosities may be increased by use of inorganic or organic bases to neutralize and ionically cross- link carboxyl groups.
- Carbomers have been used for many years as low percentage ingredients to modify cosmetic lotions, creams and gels. More recently carbomer copolymers with variously hydrolyzed varieties of polyvinyl alcohol, polyvinyl acetate or polyvinyl pyrrolidone have been used as dry components of tablets. Carbomers or copolymers as sole or majority components are not generally known.
- the new method involves application of such compositions, preferably where the polymers are in finely divided form, directly onto wounded tissue.
- This invention is placed into operation when water from blood or serum is available to initiate formation of an artificial blood clot/adhesive polymer gel.
- the polymers interact with water (H 2 O) present in blood or body fluid in an open wound, denuded tissue or burned skin to form an aqueous gel or mucilage having sufficient viscosity and adhesiveness to cover and adhere to the open wound/denuded tissue burned surface, so that bleeding or fluid loss is abated or stopped altogether.
- the " desired properties of such gels are improved for specific applications by combining the anhydrous acidic polymers with a variety of alkaline or non-alkaline thickening agents and/or additives.
- contact with water facilitates ionic interactions that tend to increase gel viscosity.
- neutralization of acid polymers occurs with use of compounds such as calcium hydroxide or magnesium hydroxide, and polyvinyl alcohol gels are thickened by borate salts.
- Use of a calcium salt improves fibrin-based clotting and gel formation.
- Use of a magnesium salt tends to impart rubbery characteristics and improve resistance to removal.
- the inventor has found that certain embodiments of these methods are useful to protect skin or damaged tissues from penetration by harmful substances or organisms and to regulate water loss.
- the methods reduce skin exposure and penetration by chemical warfare agents and other chemicals that readily diffuse through hydrophobic materials used in conventional skin protective creams. Such materials are customarily used in skin creams to permit easy spreading, and resist wiping, washing, perspiration or rainwater.
- the materials of this invention are hydrophilic yet resistant to water, and resistant to wiping when cured with water, but they can be removed readily with physiological saline solution (for example, 0.85% sodium chloride in water) or stronger solutions containing calcium or magnesium ions. Removal may be aided by wiping with materiel ranging from cotton gauze to mechanical scrapers.
- the components and products are hydrophilic, they are resistant to wetting or penetration by hydrophobic chemical warfare agents and commonly found substances such as petroleum products.
- compositions of this invention may be storage-stable, dry, liquid or paste-like comprising (a) one or more of the polyacrylic acid polymers or polyvinyl alcohol polymers described above, in one or more of their medically acceptable forms, with or without (b) one or more of the many moderately alkaline salts of calcium, magnesium and/or sodium, or other moderately alkaline organic salts or bases, in anhydrous or non-ionized form, with or without (c) being suspended in one of the hydrophilic, anhydrous, non-toxic liquids known to resist diffusion by lipophilic chemical warfare agents or environmental chemical hazards.
- Such liquids include but are not limited to polyoxyalkyene glycols, other substituted derivatives of glycol (HOCH 2 CH 2 OH), substituted derivatives of glycerol (HOCH2CHOHCH2OH), various nitrile silicone fluids, or miscellaneous anhydrous hydrophilic vehicles such as liquid surfactants.
- Compositions incorporating such liquids may be preferred to afford temporary protection of wounds or skin found at risk of exposure to contamination with chemical warfare agents, microbes, or other undesirable substances.
- carbomers or copolymers are used to defend skin from chemical warfare agents, they are known as topical skin protectants. If similar compositions are optimized to keep chemical warfare agents out of open wounds, they are known as wound sealants.
- the invention may entail use of storage-stable, dry, liquid or paste-like compositions with added minor amounts of other ingredients (preferably less than 10% of a final formulation) designed to enhance medical or military requirements for each final product.
- one of the described dry or paste-like formulations might incorporate (a) one or more of the many antimicrobial compounds, (b) indicators able to detect toxic or infectious contamination, (c) microencapsulated or insoluble decontaminating reagents, (d) substances that double as detectors and detoxifiers, (e) a pH indicator, (f) a vasoconstrictive drug, (g) camouflage pigment, and/or (h) a physical property modifier such as starch or another of the many non-toxic compounds which are known to be (or can be proven to be) safe for persistent contact with wounded or burned body surfaces.
- Dry compositions are preferred for artificial clotting of blood or serum for inimmediate hemostasis and supportive adhesive binding of damaged tissue (soft tissue splinting). Dry compositions are also preferred for creation of an artificial scab to hold clotted blood or tissue fluid components against the denuded wound surface. This arrangement permits viable epithelial cells at the wound perimeter to migrate over the denuded surface but under the protective artificial scab. Blends of dry and liquid components are preferred for use as topical skin protectants and as sealants to provide wounds with protection against chemical warfare agents and other contaminants. Dry materials (and dry materials suspended in anhydrous liquids) may be used to provide resistance to removal by wiping or washing (as with topical medicaments or cosmetics) or both wiping or washing (as by licking during veterinary use).
- compositions of the invention are advantageous for the following reasons.
- compositions may be much less expensive by comparison with hemostatic compositions derived from human or animal blood components or from other natural sources. They may form surfaces much more resistant to transit by toxic chemicals, xenobiotics, infectious agents, or excess moisture and oxygen, by comparison with other polymeric compositions or bandaging. In addition, they may be easier to store, carry in the field for instant use, and keep usable without refrigeration or special packaging by comparison with natural products. They may provide more substance for the stabilization of field wounds and reinforcement of bandages than alternatives.
- They may be more useful than alternatives currently used in hospitals (as semi- permeable dressings on burned or otherwise denuded surfaces) to promote healing. They may be used to better minimize wound contractures and scarring by comparison with currently available surgical supplies. Further, they may better serve uniquely military functions, such as co-formulation with (or under coatings of) reagents used for chemical or biological agent detection, wound decontamination, temporary topical skin protection, and/or field camouflage of casualties, as compared with known alternatives.
- compositions of this method adhere well to the wet surfaces of open wounds.
- hydrophilic formulations of this method can be expected to become adherent to skin via water associated with stratum corneum so that lipophilic substances would tend to distribute favorably into the lipophilic substances of stratum corneum.
- Such favorable properties may be realized whether the drag-containing formulation is applied as a powder or as a paste made with one of the anhydrous, hydrophilic, chemical agent-resistant liquids mentioned above.
- other advantages these methods have over previous methods include:
- the use of an alkaline compound for thickening of a wetted polymer permits alkaline hydrolysis of some chemicals (for example: GB, GD and CS) that might otherwise penetrate skin or a persistently exposed polymeric coating over skin or a wound.
- Use of a hydrophilic medium and active ingredients that are hydrophilic results in poor solubility of several skin penetrants (for example: GB, GD, NX, vesicant agents, CS, C ⁇ , and psychotomimetic agents) in the material.
- Experimental results suggest that incorporation of as little as 1% of any of several common lipophilic ingredients of other "skin protectant creams" will create diffusion pathways for passage of chemical warfare agents.
- Petrolatum, lanolin, and silicone greases are examples of such materials, which are diverse and numerous. .
- compositions of the invention have properties, features and results including the following:
- H They support use of a non-ionic anhydrous hydrophilic liquid to maintain dispersion of materials able to react in the presence of water from the skin.
- I. They are able to absorb additional perspiration after curing so that plasticizing occurs rather than blistering of the protective film J. They are able to lose moisture by evaporation to permit body cooling.
- K They can act as a buffer between tissue and atmosphere to prevent excessive tissue dehydration (or hydration, if the environment is water).
- L They act as a buffer between tissue and atmosphere to prevent excessive tissue oxygen exposure leading to free radical formation and oxidative damage to tissue.
- M They can be made to absorb CO 2 and or lactic acid given off by tissues, thereby encouraging tissue metabolism and healing.
- N. They can be formed into artificial scabs that are persistant, since polyacrylic acid and its neutralized polymers are non-biodegradable.
- O. They do not support bacterial growth since polyacrylic acid or neutralized polymers are non-biodegradable.
- P. They resist removal by animals when used in veterinary medicine or surgery.
- the invention When in the form of a paste, the invention may be spread on skin or damaged tissues with the fingers or such appliances as spatulas. If applied on a moist surface s a thick layer should preferably be applied to prevent pickup of the rapidly curing gum by adherence to the fingers or other applicator.
- a powdered formulation it may be applied in a variety of ways, as needed to meet particular requirements, and as would be readily apparent to someone having ordinary skill in this art.
- This invention makes use of the inventor's discovery that adverse effects of water can be controlled or made beneficial through use of water to activate ionization, acid-base reactions, and related adhesion of compositions to mammalian tissue for hemostasis and/or tissue protection.
- This discovery hinged on a desire to overcome adverse effects of high humidity that cancelled protection of animals exposed to VX applied onto a hydrophilic coating over skin. It was known that viscosities of aqueous polyacrylic acid dispersions are increased by alkaline neutralization. The seminal idea was that suspension of a dry acidic polymer with a dry alkaline salt in an anhydrous hydrophilic fluid might lead to formation of an adhesive gum after ionization by added water.
- soft tissue splint soon temporary as above, divalent ion sol'n artificial scab soon or late; prolonged as above or natural slough
- Each application of the methods of this invention makes use of at least one of two critical classes of components, namely polyacrylic acids or polyvinyl alcohols, in a formulation otimized for the application.
- the polyacrylic acids known as carbomers or carboxypolymethylenes are preferred components.
- carbomers are preferred for different applications and usage, as outlined above.
- non-polymeric components are critical for some applications or usages, ratios of polymeric and non-polymeric components are application specific.
- any one composition comprises at least one of the following:
- compositions are described below, both in descriptions of embodiments and in related examples.
- formulations for dry storage and applications necessarily differ from compositions with carbomers and non- polymers suspended in water or anhydrous liquid. Therefore, methods of preparation and use may be better understood in connection with descriptions of embodiments and examples. However, some features are held in common, as described below.
- Polyacrylic acid also known as carboxypolymethylene
- carbomers may be present as a homopolymer in a family of acrylic acid derivatives known as carbomers. Their polyacrylic acid strands may be cross-linked to various degrees with groups such as allyl sucrose.
- Preferred carbomers have been manufactured under trade names such as Carbopol and Noveon. Such carbomers actively absorb water, melt (without dissolving) at body temperatures, then swell.
- the acid moiety is neutralized to greater or lesser degree when the composition acquires enough water to support ionic interactions that form salts.
- Such neutralization from about pH 4 to pH 8, is known to increase mucilage viscosity in aqueous dispersions. Similar neutralization and induced tackiness is observed when water is added to the dry formulation.
- the composition includes polyacrylic acid admixed with anhydrous basic salts
- the salts provide divalent cations, such as Ca ⁇ and Mg " " " , that ionically cross-link polymer strands and increase mucilage viscosities to greater degree than monovalent cations, such as Na + or K + .
- divalent cations such as Ca ⁇ and Mg " " "
- monovalent cations such as Na + or K + .
- Physical properties, inertness and low toxicities of such neutralized carbomers are demonstrated by calcium polycarbophil, USP, which is approved by the U.S. Food and Drug administration as a safe and effective over-the-counter bulk laxative and antidiarrheal product.
- calcium polycarbophil USP includes too much calcium ion to serve as an adhesive.
- such divalent cations may ionically cross-link polyacrylic polymer strands while reinforcing the mucilage.
- Such cross-linking confers properties such as resistance to abrasion and stiffness that are suitable for retention and function as an artificial scab.
- the composition includes polyvinyl alcohol
- polyvinyl alcohol one of many commercial products may be used.
- polyvinyl alcohols known commercially as Vinols (Air Products and Chemicals, Inc.) and Elvanols (DuPont) have proven useful.
- polyvinyl alcohol is available in a wide range of degrees of hydrolysis and with corresponding water solubility and other properties.
- polyvinyl alcohols can be made more viscous and less water-soluble by a reaction with sodium borate or boric acid or by forming copolymers with carbomers.
- Such copolymers are of interest, in part, because carbomer molecules act as individual tiny sponges (microgels) when sufficient water is present to separate them.
- Polyvinyl alcohols, polyvinyl acetates, and polyvinyl alcohols can provide linkages between carbomer microgels. Such linkages may provide film-forming properties not typical of carbomers.
- clotting of blood can be facilitated by including in the gel-forming composition at least one calcium salt with a readily metabolized anion (such as gluconate or ascorbate) to provide readily available Ca "14" to facilitate clotting of blood.
- Calcium hydroxide provides enough calcium ions to serve most needs for hemostasis and acid neutralization.
- formulations made with excessive quantities of soluble calcium or magnesium salts lose adhesion to wound surfaces or normal skin. Accordingly, calcium and magnesium salts with limited solubility are preferred.
- soluble calcium or magnesium salts can be used to detach a polyacrylic gel from skin or other surface to which it may have been adhered.
- an anhydrous vasoconstrictive drug such as L-epinephrine tartrate, may be included in a formulation to restrict the diameters of leaking blood and lymph vessels.
- compositions and methods of the subject invention may be widely useful, for instance, in the following applications:
- Maintaining contact with (a) normal skin for deployment of insect repellant, decontaminating reagent, radiation reflectors, sunscreen compounds, camouflage pigments, agent detection indicators, etc., or (b) damaged body surfaces for delivery of therapeutic substances such as vasoactive compounds, antimicrobials, nutrients, or healing promoters. 4.
- Surgical use to (a) accelerate epithelialization of denuded surfaces, (b) prevent excessive formations of connective tissue during wound healing to avoid scarring, contracture distortions, or keloids, (c) minimize requirements for natural or artificial skin grafts, (d) provide a means for temporary sealing of the bleeding edges of soft internal organs such as liver, spleen, or lung prior to the application of biodegradable materials by highly skilled surgeons, and (e) stop bleeding within body orifices (e.g., nosebleed, uterine hemorrhage, and bleeding from injuries or surgery such as dental extraction or tonsillectomy).
- body orifices e.g., nosebleed, uterine hemorrhage, and bleeding from injuries or surgery such as dental extraction or tonsillectomy.
- Some novel features of this invention include: (a) significant protection from exposures to a wide variety of biological or chemical warfare, (b) opportunity for manipulation of the properties of an acrylic acid/alkaline salt hydrated product by varying the content of salts (for example, it has been found that mixtures with high content of sodium salts tend to form artificial clots that are soft and pliable, whereas calcium salts tent to impart rigidity and magnesium salts tend to impart rubbery tendencies), and (c) sealing of shallow wound cavities with suitable mixtures of calcium, magnesium and/or sodium salts. It was observed that such action was followed by production of adherent artificial scabs under which epithelial cells were protected and able to bridge larger cavities than would otherwise be epithelialized. Accordingly, such artificial scabs appear to offer protection from undesirable development of scar tissue and subsequent disfiguring contractures and/or an increased risk of cancerous tumor formation.
- This invention is designed to convert what are commonly thought to be disadvantages (of wetness in a wound or on a skin surface) into advantages.
- Existing alternatives usually address the problem of unwanted water by using one of two approaches.
- One is use of materials as barriers or as absorbers of water. Examples include use of bandaging fabrics, water-resistant polymers, skin grafts, and hydrophobic compositions, such as petroleum jelly. In many cases they are used to retain blood clotting components until clotting accomplishes in situ blockage more slowly than artificial clotting produced by the presently described invention.
- An alternative approach is to interrupt the supply of blood/water. Examples of this approach include clamping of vessels with hemostats, use of cautery, and coagulation of tissue proteins with acids.
- High efficiency is based on low costs, weights and bulk volumes needed for the anhydrous materials, and their rapid deployment potential.
- the ease of applying free-flowing powders is insured because thickening or melting occurs subsequently, in situ.
- Primary components are compatible with wet surfaces for adhesion, surface sealing and delivery of anhydrous antibiotics or other medicaments.
- hemostatic powder could be sprinkled on one or both of two opposing surfaces before they are brought together. Water from the facing surfaces induces adhesion to "glue" the surfaces together. Bandaging and stiffening materials could be adhered to damaged tissues in the same manner. In either case, the injured tissues could be stabilized to prevent additional damages. This soft tissue splinting could serve the same purpose as splinting of fractured bones: to minimize subsequent damage.
- applications to wounds can be built up to stabilize ragged edges and maintain an osmotic balance such that the damaged tissues can be maintained with minimal drying out or displacement during transport of a patient to a surgical facility.
- compatibility with wet surfaces means that products can be applied on perspiring skin or during rainfall, to deliver detoxifying reagents onto contaminated skin or to provide prophylaxis against contact with chemical warfare agents.
- Adhesion is activated at the source of bleeding or fluid loss. Since direct sealing action proceeds outward from the damaged site, this sealing orientation provides maximal efficiency in blocking vessels, or coating denuded surfaces and normal skin. Also, this orientation permits observation of any arterial blood breakthroughs so that, if necessary, pressure occlusion can be maintained during the brief time period (usually less than 1 minute) that is required for completion of the acid-base reaction or melting enough to provide contact with surfaces and effective reinforcement of the seal.
- time for maximal adhesion is related to the amount of blood/water already present and to the volume and distribution of the powder to be wetted. Larger boluses of hemostatic powder and increased diffusion time are needed as volumes and flow rates of blood increase.
- This invention includes compositions and methods for use of unadorned polymers as the most simple embodiment of the novel concept that a biocompatible polymeric powder can combine with the water of blood to create an artificial clot in situ.
- polyacrylic acid powders need not be neutralized to satisfy some uses described for multi-component formulations.
- GRAS safe
- polyacrylic acids are frequently and safely used in dentistry.
- demonstrations of safety and efficacy are generally required for new uses or mixtures of GRAS substances. This fact indicates that safety testing may be required for each proposed composition and for use of unadorned polyacrylic acid powders on wounded tissue.
- a preferred operation of this invention involves formulation of a finely divided anhydrous mixture including a polymeric acid and at least one non- corrosive alkaline calcium salt, so that the packaged, unreacted components can be applied onto a bleeding wound or other body surface.
- Such action leads to ionization or melting of the polyacrylic acid to form an adhesive gel or gum that tenaciously adheres to damaged tissues for service as an artificial blood clot or barrier layer.
- the addition of water to dry polyacrylic acid lowers the glass transition temperature from above 115 degrees centigrade to well below mammalian body temperatures. It is this melted product (water plasticized) that adheres to wet tissues.
- the preferred ratio of polymer to calcium ion donor ratio will be as needed to yield a gel pH of about 7.4 at the gel/tissue interface.
- the preferred calcium ion donor formulation will be as needed to approximate osmolarity of 0.85% sodium chloride solution.
- the preferred non- polymeric formulation will provide a physiological balance of sodium, potassium, calcium and magnesium ions at the gel/tissue interface, in the presence of the particular carbomer or copolymer, during the expected period of gel/tissue contact. It is noted that there is one prior composition that yields a familiar substance by means of a process somewhat similar to that of the described invention.
- That composition also involves the formulation of powdered material, use of water to activate adhesion of the primary material to particulate and fibrous substrates, and retention of the ensuing mixture in situ until curing takes place.
- that substance is used to block the unwanted flow of watery fluids and to create water-resistant coatings.
- that prior substance operates by trapping water in hydrated form. Furthermore, it cures slowly and is far too alkaline and inflexible for biocompatibility. That substance is known as portland cement.
- this invention consists of a method for artifically clotting blood or body fluids by employing their water content to change anhydrous polymeric particles into a gel that adheres to wet tissue sufficiently to block flow from blood vessels or damaged surfaces.
- This method can be implemented with any one of the carbomers (or their copolymers) and carbomer compositions as described above, if the powdered composition is (a) applied to the tissue in quantity sufficent to absorb all watery exudate (blood or fluids), and (b) held firmly in place until normal clotting has sealed bleeding vessels, or adhesion to tissue is sufficient to block flow from embedded arteries.
- the effective carbomers consist of (1) various forms of polyacrylic acid and or other biocompatible polymers (such as polyvinyl alcohol, polyvinyl acetate, or polyvinyl pyrrolidone).
- the compositions include anhydrous alkaline substances that neutralize the various forms of polyacrylic acid, or copolymers, to (a) increase the viscosities of the gels, and/or (b) modify formulations to serve intended surgical uses. These uses include hemostasis, wound sealing to retain body substances, formation of protective coatings to exclude injurious substances, and/or fostering of healing and epithelialization.
- alkaline components in the art of polyacrylic acid use is the neutralization of acidic sites of polymer chains.
- Such neutralization is often used to substantially increase gel viscosity and adhesive strength of compositions largely composed of water.
- water is excluded from compositions until it is available from blood or tissue fluids.
- dry divalent alkaline salts of calcium and/or magnesium are mixed with dry polymers using equpment used in the art to prepare dry compositions before packaging. Dry divalent salts add to gel viscosity (when moistened), apparently by forming ionic links between adjacent polymer filaments, and with negatively-charged sites of tissue biopolymers, such as proteins and peptides when the divalent cations are mobilized by water to interact with anionic carboxylic sites of polyacrylic acid polymers.
- polyacrylic acid known commercially as Carbomer 941
- Anhydrous sodium borate elevates pH, absorbs water of hydration and, in the presence of water, reacts with polyvinyl alcohol to form a poorly soluble gel.
- polymeric or polymeric and non-polymeric components become organized as a hydrophilic gel that adheres to damaged tissues while entrapping lost cells, proteins and salts. Such gels adhere without the clotting time delay observed with blood components.
- Some of the gels may present as films. Other gels may evolve into artificial scabs that are semi-permeable to water, oxygen, and carbon dioxide.
- the method of the invention may include the further step of applying pressure to the site of the wound/denuded area/burn, which would be effective to collapse blood vessels and restrict further hemorrhage while sufficient water is absorbed by the composition to form a gel and staunch blood flow.
- the duration of this step will vary with the size of hemorrhaging vessels, sufficiency and amount of the composition, and avoidance of excessive shearing movement, but is expected to begin immediately after application of the composition and may be completed within about one to five minutes. If the powder is not distributed effectively at first, the operator may need to move it around until all powder is wetted. If insufficient powder has been applied initially, more can be applied over any wet spot until hemostasis is complete. If it is appropriate to reinforce or extend the perimeter of an existing gel, more powder and/or more water may be added. However, water should be applied gradually to avoid softening of the existing gel.
- the powdered composition is retained behind a membrane or enclosed within a bag of polyacrylic acid film or carbomer-copolymer film, with or without incorporated calcium ions to aid fibrin- based clotting of blood.
- the sequestered composition is further enclosed within a sterile heat-sealed envelope designed to be readily opened (with a tear strip or similar device) so the polymer film is presented on one side of the envelope residue.
- the back of the envelope is used to separate an operator's fingers from the film and/or the composition. The operator would be expected to place the film against the wound to displace pooled blood and apply indirect finger pressure (about 5-10 pounds/square inch) over any apparently transected blood vessel(s).
- the film disintegrates, in contact with water of blood or damaged tissue, to permit wetting of the released bolus of powder for adherence to wounded tissue.
- the loaded sponge is folded within the envelope to retain the powdered composition.
- This arrangement permits the user to release the fold and apply the composition onto the target site.
- the sponge and envelope may be held in place then left to serve as an external reinforcement of the gel.
- the sponge and envelope might be wrapped with suitable pressure bandaging to avoid displacement.
- a volume of composition at least equal to the volume of a deep wound may be required.
- the envelope may be removed so that additional loaded sponges may be deployed over or adjacent to the first one.
- compositions might be applied in large volume (as desired) directly into a life-threatening wound from a large package, dispensed from a puffer tube onto an oozing, burned or abraded surface, or a small loaded pad might be applied directly over a superficial wound (as with an adhesive bandage).
- compositions might be sifted from a shaker type container, or blown out of a pressurized container, etc.
- packaging might be designed to satisfy military requirements, non-military users of this invention might employ a wide variety of packaging available to those skilled in the art. However, packaging must store the composition in desiccated form for rapid delivery at a wound or body surface.
- compositions Once the composition has been applied to the targeted site, additional water may be added (slowly) to the outside surface of the composition to provide a durable anti-hemorrhagic plug of a wound or to improve the thickness and protective capacity of a wound sealant after blood flow and water diffusion has been stopped.
- additional water may be added (slowly) to the outside surface of the composition to provide a durable anti-hemorrhagic plug of a wound or to improve the thickness and protective capacity of a wound sealant after blood flow and water diffusion has been stopped.
- One of the most important uses of the described formulations would be as a readily carried sterile powder within sterile packaging designed to permit immediate control of hemorrhage under field conditions. Typical components might be packaged inexpensively within readily deployable heat-sealed envelopes or pouches. The contents of these packages would be added and sealed up under sterile conditions. Any inorganic components (such as calcium hydroxide) could be readily sterilized with dry heat.
- Soft Tissue Splint Another embodiment of the invention entails a skin and soft tissue adhesive composition comprising at least one of the above-described gel-forming compositions. If bleeding is considered to need correction, a preferred composition might be identical to that of a dry powder optimized to control hemostasis. If the primary consideration is to stabilize and protect tissue (as during an expected long stay in an ambulance), the preferred non-polymeric components would be different. For tissue protection, the preferred non- polymeric formulation will provide a physiological balance of sodium, potassium, calcium and magnesium ions at the gel/tissue interface, in the presence of the particular carbomer or copolymer, during the expected period of gel/tissue contact.
- the preferred polymer/non-polymeric ion donor ratio will be as needed to yield a gel pH of about 7.4 and approximate osmolarity of 0.85% sodium chloride solution at the gel/tissue interface.
- the non- polymeric components may include antimicrobials as indicated in surgical art.
- the gel-forming compositions react with the water to form an adhesive gel that adheres to skin and soft tissue.
- Use of a hemostatic powder to 'glue' surfaces of a wound together might be indicated to support and stabilize (splint) damaged soft tissues. Later, the surgeon working on the injured individual will likely want to remove the composition in the operating room.
- the constituted adhesive gel would serve as a temporary expedient and soft tissue splint.
- the composition may include one or more of an antibiotic, blood-clotting enzymes, decontaminating reagents, detoxifiers, pH indicators, vasoconstrictive agents, or compositions capable of indicating the presence of toxic or infectious compounds.
- the dry components of a tissue glue/soft tissue splint might be formulated with deionized water to form a paste or mucilage.
- a formulation might be used as a soft tissue splint if hemorrhage or fluid loss has been controlled.
- Such a formulation may have the same dry components, in the same relative proportions, as needed to protect tissues with a dry soft tissue splint composition.
- Such a formulation could be made by applying the existing art for formulation of moderately viscous consumer products such as dental adhesives.
- Such pre-formed gels may be packaged in collapsible tubes of various designs, as known in the art. Accordingly, such sterile compositions may be extruded or expelled directly onto denuded surfaces. They might be spread through apposition of damaged tissues by gentle manipulation of adjacent undamaged surfaces or by use of sterile sponges, instruments, or gloved hands.
- tissue glues either dry or as pre-formed gels
- adherence of carbomers to skin might be exploited for temporary attachment of small objects to skin.
- electrocardographic electrodes might be attached to the chest to permit recording during strenuous exercise.
- a preferred formulation would employ one of the carbomers known in the art as electrolyte resistant.
- a patch could be constructed with a high electrolyte concentration in a core in contact with a metal lead and an electrolyte- free perimeter arranged to assure firm attachment to moistened skin.
- a carbomer with balanced electrolytes might serve to attach costume jewelry to moistened ear lobes.
- formulations of the above-described compositions can be used to protect denuded tissue from further damage. Such damage might ensue from losses of body substances (such as water, blood, plasma, serum, proteins, electrolytes, nutrients), and from access of and further damage by normal environmental substances (such as oxygen, dirt, foreign protein antigens, pathogens, saprophytes, etc.).
- Preferred compositions for this embodiment will provide tissue protection, and accordingly they will be formulated with physiologically balanced electrolyte ions to make a gel providing physiologic osmotic and pH properties.
- Such compositions are preferably formulated with enough light magnesium oxide to make a slightly rubbery product but the MgO/polymer ratio will be low enough to assure firm adhesion to damaged tissue.
- compositions will be application as a dry sterile powder sifted or dropped directly onto wounded or burned surfaces. Such surfaces should be free of obvious or likely contamination but losing blood or tissues fluids rapidly enough to establish a gel within about ten minutes or less. In such cases, sufficient powder should be applied (or re-applied) to assure an initial gel thickness of about two to five mm.
- the dry components might be formulated with deionized water to . form a paste or mucilage, as described for soft tissue splinting or use as a tissue glue.
- the art for packaging and deployment of described pre-formed gels might be used to generate artificial scabs on denuded surfaces exhibiting sparse loss of blood or fluids.
- Formulations designed to provide tissue protection represent preferred compositions for artificial scab formation. If used as dry powders, they would be sifted into a wound with intent to generate a gel of thickness between about two and about five mm thick. If the wound does not provide enough water to generate a gel at least two millimeters thick, sterile water might be added drop-wise to wet the wound before and/or after application of the powdered composition.
- a preformed aqueous gel should be spread on a denuded surface to a depth of about five to ten millimeters.
- a further embodiment is suggested by observations made during actual military conflict. Formulations later observed to form artificial scabs were applied to wounds of rabbits made by completely removing full thickness skin as a disc about three centimeters wide. This was done with anesthetized rabbits to test protection against contamination with chemical warfare agent CS, then in uses in military combat situations. Accordingly, control wounds were exposed to CS without such protection. The control wounds developed normal scabs and their skin perimeters rapidly contracted to substantially reduce areas of exposed muscle. This is a normal and desirable response of loose skin, as found on rabbits and cats. Perimeters of similar human wounds do not contract significantly.
- a preferred composition (a carbomer, balanced electrolytes, light MgO, pH near 7.4, osmolarity like physiological saline, antimicrobial content) might provide a protective shield to limit development of fibroblastic tissue and support epithelialization.
- This shield could serve as an artificial scab to protect the wounded area from losses of body substances and further damage, as caused by environmental substances or solar radiation, that often leads to formation of disfiguring scar tissue.
- This method might be used, with application of a preferred composition in dry form or pre-formed aqueous gel, to promote migration of epithelial cells over underlying tissue.
- an open wound or denuded or burned body surface may be protected from environmental access and further damage by chemical warfare agents, biological warfare agents, noxious industrial substances, and or other toxic substances that may constitute hazards to unprotected wounds or tissues.
- the open wound, denuded body surface or burned skin may be exposed to therapeutic substances incorporated as desiccated soluble drugs that would become dissolved in water from the tissue and gel. They would diffuse preferentially into the tissues from the mucilage.
- these drugs might include (but would not be limited to) antibiotics and sulfonamides, or trauma reduction agents such as antioxidants and nutrients.
- growth factors or cytokines useful for keeping cells alive and proliferating might be included. These could healing under a protective covering of polymeric gel and incorporated blood product residues.
- the invention contemplates methods for reducing skin exposure and penetration by chemical warfare agents, as described above.
- This method comprises the step of coating skin with a composition comprising (a) at least one of the compositions selected from the group consisting of
- anhydrous hydrophilic liquid capable of resisting penetration of chemical warfare agents or other noxious compounds, in which the polyacrylic acid and the alkaline salt are suspended and which permits the polyacrylic acid to form a gel in the presence of water.
- anhydrous hydrophilic fluid would be selected from among those found to resist diffusion by various lipophilic chemical warfare agents.
- Such fluids include (but are not limited to) nitrile silicone fluid, polyoxyalkylene glycols, and anhydrous liquid surfactants; and
- composition optionally, one or more of decontaminating reagents, detoxifiers, camouflage pigment, pH indicators, agents capable of detecting the presence of toxic or infectious compounds, sodium borate, calcium hydroxide, calcium gluconate, magnesium oxide, etc.
- the composition may further include an anhydrous hydrophilic media or liquid, in which the polyacrylic acid and the alkaline salt are suspended and which permits the polyacrylic acid to form a gel in the presence of water.
- anhydrous hydrophilic media or liquid in which the polyacrylic acid and the alkaline salt are suspended and which permits the polyacrylic acid to form a gel in the presence of water.
- the invention involve a method for wound protection that relates to a family of compositions (and the use thereof) that contain at least one of the above-described compositions, which further contains an alkaline salt that may be used as a dry powder or be suspended in an anhydrous hydrophilic media, or in an aqueous gel.
- an alkaline salt that may be used as a dry powder or be suspended in an anhydrous hydrophilic media, or in an aqueous gel.
- the polyacrylic acid known commercially as Carbopol 941 (and related acidic polymers) will react rapidly in the presence of water to form gels with sodium salts, or poorly soluble gums with calcium or magnesium salts.
- the dry reactants might be suspended in poorly-soluble hydrophilic liquid media, such as a polyoxyalkyene glycol or nitrile silicone fluid.
- a polyoxyalkyene glycol or nitrile silicone fluid Such fluids were identified in screening tests designed to detect resistance to transit by chemical warfare agents. Accordingly, such compositions are useful to protect skin from penetration by harmful substances or organisms and may be useful to protect damaged tissues and to regulate water loss. Thus, the compositions could both "stick" to wounded tissue and extend over neighboring skin to seal off a wound. Examples of formulations that protected animals and human skin from irritant or vesicating effects of CS-2, and animals from the lethal effects of 4 LD5 0 doses of VX, are given below.
- Formulations for use as wound sealants may include antimicrobials, vascular constrictor or anti-inflammatory drugs, pH indicators or systems, chemical agent indicators/detoxifiers, sunscreens, camouflage pigments, or other components added to support particular military applications.
- Antibiotics or other medicaments can be incorporated into modified formulations intended for wound or burn dressing to provide intimate, continuous contact with the damaged tissue.
- the suspensions could be applied readily as creams or pastes but they would absorb ambient and tissue water to cure in situ as tough films.
- Packaging and handling of polymeric and non-polymeric components in suspensions made with non-aqueous liquids may be expected to resemble methods described with regard to aqueous gels for embodyment as tissue glue/soft tissue splints or in artificial scabs.
- Another embodiment concerns use of the methods and compositions described for wound protection in a different role as drug delivery vehicles.
- the same dry or pre-formed gel compositions might be used primarily to deliver antimicrobials or a variety of other drugs into a wound or other surface of a patient.
- drugs currently given systemically to achieve useful concentrations in wounded tissues or diseased surfaces
- hydrophilic gels could be delivered locally from the described hydrophilic gels.
- higher local drug concentrations and lower blood concentrations could be achieved, if only local effects are needed.
- such local use of hydrophilic gels might be expected to promote transfer of hydrophobic drugs into hydrophobic skin and tissue membranes.
- kits In a different embodiment, the invention contemplates various kits that can be used in conjunction with any of the above-mentioned embodiments, and other embodiments not described in so much detail. Other kits may be used for hemostasis, soft tissue splinting, artificial scabs, topical . protectants, wound sealants and as drug delivery vehicles.
- the kits must have, as a minimum and packaged in association, one of the above-described compositions and either a dispenser for applying the composition as desired or instructions as to how to properly use and apply the composition.
- the dispenser may be, for instance, a non-woven fabric, a woven fabric, a tube, a bandage impregnated with the composition, or a container having an opening through which the composition may be dispensed.
- one kit may be designed for reducing blood or fluid loss from open wounds, denuded tissue or burned skin in a mammal.
- the kit comprises, packaged in association,
- a gel-forming composition comprising at least one of the above-described compositions, which upon application of the composition to the site of the open wounds, denuded tissue or burned skin, reacts with water present in blood or other bodily fluid exposed in the site to form a gel that adheres to the site and reduces loss of blood or bodily fluid, and (ii) a dispenser for applying the composition to open wounds, denuded tissue or burned skin.
- kit for reducing skin exposure and penetration by chemical agents that could include GB, GD, VX, HD, CS-2, CN and EA3580. It comprises, packaged in association, (i) a gel-forming composition comprising at least one of the above-described compositions; and
- optional components may include one or more of an antibiotic, blot-clotting enzymes, decontaminating reagents, detoxifiers, camouflage pigment, pH indicators, vasoconstrictive agents, agents capable of detecting the presence of toxic or infectious compounds, starch, sodium borate, calcium hydroxide, calcium gluconate, magnesium oxide and borax.
- the anhydrous hydrophilic liquid is preferably one of polyoxyalkylene glycols, nitrile silicone oils, or certain anhydrous surfactant liquids.
- M-5 ointment The topical skin protectant known as M-5 ointment was the only composition issued by the U.S. Army during World War II for skin defense against chemical agents. It was effective against HD but ineffective or detrimental with other agents. Its lipophilic base tended to increase agent penetration of skin by trapping water in the barrier layer of the epidermis. An oxidizer in M-5 ointment converted one of the nerve agents into a severe skin irritant. Therefore, M-5 ointment was withdrawn from issue.
- Formulation B gm polyvinyl alcohol, 2 gm dehydrated sodium borate, 3 gm Carbowax 1500 Formulation C 15 Gm Carbopol 941 (B.F. Goodrich brand of carboxypolymethylene), 7 gm dibasic sodium phosphate (anhydrous Na 2 HPO 4 ), 8 gm light magnesium oxide, 70 gm UCON LB 1715 (Union Carbide Corp. brand of polyoxyalkylene glycol)
- Formulation D 80 Gm Pluronic P65 (anhydrous surfactant liquid), 10 gm borax, 5 gm sodium carbonate, 5 gm Vinol 205 (partially hydrolyzed polyvinyl alcohol)
- Formulation F 90 gm Pluronic P65, 5 gm Carbopol 941, 5 gm calcium oxide
- Depilated rabbits were coated with the described formulations, which were challenged with a standardized exposure dose of CS-2 (CS riot control agent treated to facilitate aerosolization).
- the combination of alkaline salts in formulation A was selected to produce a product of about pH 9, to be safe for skin yet facilitate rapid alkaline hydrolysis of the limited amount of certain lipophilic skin penetrants that can dissolve in a hygroscopic polyglycol derivative.
- Starch and various other polysaccharides absorb water and act as stabilizers of the very soluble polyglycols.
- Anhydrous sodium borate in Formulation B elevates pH, absorbs water of hydration and, in the presence of water, reacts with polyvinyl alcohol to form a poorly soluble gel.
- Carbopol 941 (carbomer 941) of formulation C is one of several carbomers that, in the presence of water, react rapidly to form gels with sodium salts, or poorly-soluble gums with magnesium salts.
- UCON LB- 1715 is a syrupy anhydrous liquid found to resist diffusion of lipophilic substances, apparently because it is hydrophilic although it is not very soluble in water. The ingredients were readily worked with a spatula to yield pastes with readily soluble Carbowax 1500 or less soluble hydrophilic media such as Pluronic P65 or UCON LB-1715. Each of these formulations was found to visibly reduce skin redness and latent blistering (Nikolsky's effect) produced by CS-2 on control skin.
- Formulation G 3 gm light magnesium oxide, 3 gm Carbopol 941, 14 gm UCON LB-1715 (Union Carbide Corp. brand of polyoxyalkyene glycol)
- Formulation I 3 gm magnesium carbonate, 3 gm Carbopol 941 , 14 gm UCON LB- 1715
- Formulation L 3 gm light magnesium oxide, 3 gm anhydrous dibasic sodium phosphate, 6 gm Carbopol 941, 28 g UCON LB-1715
- CS-2 was sifted into control wounds, and over wounds coated with applications of wound sealant suspensions or their dry powdered components.
- Applied suspensions represented by Formulations C, D, E and F
- dry powders similar ratios of dry components without an anhydrous liquid
- EXAMPLE 6 The first dry mixture applied to freely bleeding rabbit wounds consisted of a formulation called #312G. This consisted of 4 gm Carbopol 934, 2 gm Ca(OH) 2 , 1 gm calcium gluconate, and 0.08 Gm L-epinephrine bitartrate. About half of a teaspoonful (about 8 mm 3 ) of #312E powder was loaded onto a 2x2- inch cotton gauze surgical sponge. A post-experimental rabbit was anesthetized. Scissors were used to cut though the marginal ear vein of one ear. The loaded sponge was clamped around the cut with finger pressure and held for about 15 seconds before pressure was released. It was then noted that bleeding had been stopped completely.
- #312G This consisted of 4 gm Carbopol 934, 2 gm Ca(OH) 2 , 1 gm calcium gluconate, and 0.08 Gm L-epinephrine bitartrate. About half of a teaspoonful (about 8 mm
- any one of several carbomers can be used, without added alkaline salts, to illustrate how water activates such material to glue tissues together.
- Persons are asked to wet one thumb and first finger with tap water. A small amount (1-2 mm 3 ) of a carbomer powder is placed on the moistened finger. The person is asked to close the thumb on the first finger to hold the powder firmly for about 10 seconds. In most cases the polyacrylic acid becomes moistened enough to lightly glue the thumb and finger together.
- Alkaline salts are not required, but results of documented studies show that neutralized carbomers or transesterified polyvinyl alcohol gums exhibit improved adhesive strength, adhesion to tissues, and resistance to removal in the presence of excess water. However, it was concluded that an unadorned polymer provides a convenient demonstration to show how water from blood can activate hemostasis by forming an adhesive gum with a carbomer.
- the carbomer/salt formulations were spread on two 4x4- inch 12 ply sponges exposed by opening an 8x8 cm window in their sterile packaging envelope. This assembly was folded to permit one-hand delivery of the enclosed formulation (by release of the fold) directly over the embedded needle. It was concluded that the method of powder application could be improved if a film of polyacrylic acid could be used to confine a bolus of powder for more convenient delivery to a site of major hemorrhage.
- a thin layer of the 974P/MgO gel detached from the chicken breast was spread on uminum foil.
- One ply of gauze sponge scrim was embedded in the gel. The gel was distributed evenly under a sheet of polyethylene film, which was then peeled off the layer of scrim and gel.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15915602A IL159156A0 (en) | 2001-06-22 | 2002-06-20 | A gel forming composition containing a polyacrylic acid |
CA2449436A CA2449436C (en) | 2001-06-22 | 2002-06-20 | Compositions and methods for reducing blood and fluid loss from open wounds |
AU2002350088A AU2002350088A1 (en) | 2001-06-22 | 2002-06-20 | Compositions and methods for reducing blood and fluid loss from open wounds |
EP02780883A EP1408902A4 (en) | 2001-06-22 | 2002-06-20 | Compositions and methods for reducing blood and fluid loss from open wounds |
IL159156A IL159156A (en) | 2001-06-22 | 2003-12-02 | Bioadhesive gel or mucilage containing a carbomer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30038401P | 2001-06-22 | 2001-06-22 | |
US60/300,384 | 2001-06-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003000155A2 true WO2003000155A2 (en) | 2003-01-03 |
WO2003000155A3 WO2003000155A3 (en) | 2003-07-03 |
Family
ID=23158880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/019554 WO2003000155A2 (en) | 2001-06-22 | 2002-06-20 | Compositions and methods for reducing blood and fluid loss from open wounds |
Country Status (6)
Country | Link |
---|---|
US (1) | US7303759B2 (en) |
EP (1) | EP1408902A4 (en) |
AU (1) | AU2002350088A1 (en) |
CA (1) | CA2449436C (en) |
IL (2) | IL159156A0 (en) |
WO (1) | WO2003000155A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063922A1 (en) * | 2002-01-31 | 2003-08-07 | Aesculap Ag & Co. Kg | Haemostatic agent containing polyvinyl alcohol and provision of the same for medical use |
WO2008102150A2 (en) * | 2007-02-21 | 2008-08-28 | Pharmacure Health Care Ab | Composition for combating epistaxis |
EP2145617A1 (en) * | 2008-04-04 | 2010-01-20 | Ludzker, Benjamin | Gel formulation |
GB2488915B (en) * | 2011-03-11 | 2020-09-30 | Medtrade Products Ltd | Haemostatic material |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060216267A1 (en) * | 2002-08-20 | 2006-09-28 | Kovacs Stephen G | Hydrophobic elastomeric polymer chemistry device for inhibiting the growth of onychomycosis and urushiol-induced allergic contact dermatitis |
US7074425B2 (en) * | 2002-09-26 | 2006-07-11 | Bonewax, Llc | Hemostatic compositions and methods |
ITMI20030414A1 (en) * | 2003-03-06 | 2004-09-07 | Biofarm S R L Ora Biofarmitalia S P A | BUFFER WITH GEL LAYER WITH COSMETIC OR THERAPEUTIC ACTIVITY. |
US7955616B2 (en) * | 2003-09-23 | 2011-06-07 | Orthocon, Inc. | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
WO2005034726A2 (en) * | 2003-09-23 | 2005-04-21 | Ortho Therapeutics, Llc | Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects |
CN1856283A (en) | 2003-09-23 | 2006-11-01 | 奥斯治疗有限公司 | Bioabsorbable putty-like hemostatic implants |
WO2005089472A2 (en) * | 2004-03-17 | 2005-09-29 | Genzyme Corporation | Anti-adhesion spraying |
US20060178609A1 (en) | 2005-02-09 | 2006-08-10 | Z-Medica, Llc | Devices and methods for the delivery of molecular sieve materials for the formation of blood clots |
EP1853326B1 (en) * | 2005-02-15 | 2016-06-15 | Virginia Commonwealth University | Mineral technologies (mt) for acute hemostasis and for the treatment of acute wounds and chronic ulcers |
JP5204646B2 (en) * | 2005-04-25 | 2013-06-05 | マサチューセッツ インスティテュート オブ テクノロジー | Compositions and methods for promoting hemostasis and other physiological activities |
US20070129630A1 (en) * | 2005-12-07 | 2007-06-07 | Shimko Daniel A | Imaging method, device and system |
US20070135706A1 (en) * | 2005-12-13 | 2007-06-14 | Shimko Daniel A | Debridement method, device and kit |
WO2008018892A2 (en) * | 2005-12-22 | 2008-02-14 | Pluromed, Inc. | Methods and kits for treating lacerations and puncture wounds using inverse thermosensitive polymers |
US9084837B2 (en) * | 2006-04-25 | 2015-07-21 | Massachusetts Institute Of Technology | Compositions and methods for affecting movement of contaminants, bodily fluids or other entities, and/or affecting other physiological conditions |
US8938898B2 (en) | 2006-04-27 | 2015-01-27 | Z-Medica, Llc | Devices for the identification of medical products |
US7604819B2 (en) | 2006-05-26 | 2009-10-20 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US8202532B2 (en) | 2006-05-26 | 2012-06-19 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US7968114B2 (en) | 2006-05-26 | 2011-06-28 | Z-Medica Corporation | Clay-based hemostatic agents and devices for the delivery thereof |
US20080014251A1 (en) * | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
JP5597836B2 (en) * | 2006-08-04 | 2014-10-01 | ケンジー ナッシュ コーポレイション | Biomimetic compound and synthesis method thereof |
WO2008127287A2 (en) * | 2006-10-11 | 2008-10-23 | Biolife, L.L.C. | Materials and methods for wound treatment |
US7922064B2 (en) * | 2007-05-16 | 2011-04-12 | The Invention Science Fund, I, LLC | Surgical fastening device with cutter |
US7832611B2 (en) * | 2007-05-16 | 2010-11-16 | The Invention Science Fund I, Llc | Steerable surgical stapler |
US20080287987A1 (en) * | 2007-05-16 | 2008-11-20 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Dispensing system for tissue sealants |
US7798385B2 (en) * | 2007-05-16 | 2010-09-21 | The Invention Science Fund I, Llc | Surgical stapling instrument with chemical sealant |
US7810691B2 (en) * | 2007-05-16 | 2010-10-12 | The Invention Science Fund I, Llc | Gentle touch surgical stapler |
US8485411B2 (en) | 2007-05-16 | 2013-07-16 | The Invention Science Fund I, Llc | Gentle touch surgical stapler |
US7823761B2 (en) * | 2007-05-16 | 2010-11-02 | The Invention Science Fund I, Llc | Maneuverable surgical stapler |
US8771725B2 (en) | 2007-10-12 | 2014-07-08 | Chesson Laboratory Associates, Inc. | Poly(urea-urethane) compositions useful as topical medicaments and methods of using the same |
US20090112243A1 (en) * | 2007-10-25 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Surgical cutter with dispensing system for tissue sealants |
US20090112256A1 (en) * | 2007-10-30 | 2009-04-30 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Suturing device with tissue sealant dispenser |
US20110054375A1 (en) * | 2007-11-27 | 2011-03-03 | Hans Smola | Dressing comprising polyacrylate particles and use thereof |
US20090143816A1 (en) * | 2007-11-30 | 2009-06-04 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Grasper with surgical sealant dispenser |
US20090275904A1 (en) * | 2008-05-02 | 2009-11-05 | Sardesai Neil Rajendra | Sheet assemblies with releasable medicaments |
US8999297B2 (en) * | 2008-07-11 | 2015-04-07 | Inter-Med, Inc. | Hemostatic agent |
WO2010068509A1 (en) * | 2008-11-25 | 2010-06-17 | Biolife, L.L.C. | Hemostatic wound dressings |
WO2010102283A2 (en) * | 2009-03-06 | 2010-09-10 | Jack Mentkow | Hemostatic agent composition, delivery system and method |
US20100226873A1 (en) * | 2009-03-06 | 2010-09-09 | Biolife, L.L.C. | Hemostatic Composition with Magnetite |
US8110208B1 (en) | 2009-03-30 | 2012-02-07 | Biolife, L.L.C. | Hemostatic compositions for arresting blood flow from an open wound or surgical site |
US9439941B2 (en) | 2009-12-14 | 2016-09-13 | The University Of Hong Kong | Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells |
US8409628B2 (en) | 2010-02-04 | 2013-04-02 | Penguin IP Holdings, Inc. | Methods and compositions for oxygenation of skin to treat skin disorders |
US20110200683A1 (en) * | 2010-02-16 | 2011-08-18 | Piper Medical, Inc | Hydrogen peroxide solution producing first aid substance, packaging, and treatment |
WO2011123619A2 (en) | 2010-03-31 | 2011-10-06 | Penguin Ip Holdings Inc. | Permeable mixtures, methods and compositions for the skin |
US9119605B2 (en) | 2010-05-06 | 2015-09-01 | Zimmer, Inc. | Synthetic polymer adhesives and methods for making, using and delivering the same |
US8858969B2 (en) | 2010-09-22 | 2014-10-14 | Z-Medica, Llc | Hemostatic compositions, devices, and methods |
EP2637707A4 (en) | 2010-11-09 | 2014-10-01 | Kensey Nash Corp | Adhesive compounds and methods use for hernia repair |
PL395069A1 (en) * | 2011-05-31 | 2012-12-03 | Warszawski Uniwersytet Medyczny | An analgesic pharmaceutical composition for oral administration |
US8387798B1 (en) | 2012-04-27 | 2013-03-05 | Abdulmohsen E. A. H. Al-Terki | Mutiple oral and nasal surgical procedures method and kit |
US10022083B2 (en) | 2011-06-02 | 2018-07-17 | Abdulmohsen E. A. H. Al-Terki | Multiple oral and nasal surgical procedures method and kit |
US20130202656A1 (en) | 2012-02-03 | 2013-08-08 | Dynasil Biomedical Corporation | Systems and kits for the fabrication of tissue patches |
US9220646B2 (en) * | 2012-03-30 | 2015-12-29 | Kimberly-Clark Worldwide, Inc. | Absorbent articles with improved stain decolorization |
BR112014031439A8 (en) | 2012-06-22 | 2023-01-31 | Z Medica Llc | HEMOSTATIC AND WOUND DEVICES AND DRESSINGS AND PROCESSES FOR PRODUCING HEMOSTATIC AND WOUND DEVICE |
EP2968651B1 (en) * | 2013-03-15 | 2020-10-21 | Cook Medical Technologies LLC | Adhesive medical products and methods for treating gastrointestinal lesions |
US11931227B2 (en) * | 2013-03-15 | 2024-03-19 | Cook Medical Technologies Llc | Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding |
WO2015089626A1 (en) | 2013-12-16 | 2015-06-25 | The University Of British Columbia | Self-fueled particles for propulsion through flowing aqueous fluids |
AU2016307447A1 (en) | 2015-08-07 | 2018-02-22 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9833538B2 (en) | 2015-08-07 | 2017-12-05 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
US9540548B1 (en) | 2015-08-07 | 2017-01-10 | Xcede Technologies, Inc. | Adhesive compositions and related methods |
IL247786B (en) | 2016-09-12 | 2019-08-29 | Plotkin Alexander | Wound covering with haemostatic action and the method of its creation |
JP2020517399A (en) * | 2017-04-28 | 2020-06-18 | クック・メディカル・テクノロジーズ・リミテッド・ライアビリティ・カンパニーCook Medical Technologies Llc | Method and composition for bimodal treatment of digestive tract lesions with active bleeding |
US11452798B2 (en) | 2017-09-27 | 2022-09-27 | Cook Medical Technologies Llc | Crosslinking submucosal injectate system |
US20210106717A1 (en) * | 2019-10-10 | 2021-04-15 | Cook Medical Technologies Llc | Bonded powders for the treatment of bodily lesions |
US20230330297A1 (en) * | 2022-04-15 | 2023-10-19 | Waldir Teixeira Renó | Homeostatic single layer dressing |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133326A (en) * | 1994-08-31 | 2000-10-17 | Pfizer Inc | Compositions and methods for decreasing sebum production |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249458B (en) * | 1960-10-14 | 1967-09-07 | Mmisterul Industnei Petrolului si Chimiei Bukarest | Film-forming skin protection agent |
US4215106A (en) * | 1978-04-07 | 1980-07-29 | Annenkova Valentina M | Local hemostatic |
DE3224382A1 (en) * | 1982-06-30 | 1984-01-12 | Beiersdorf Ag, 2000 Hamburg | HYDROGEL-BASED FABRIC MATERIAL AND METHOD FOR THE PRODUCTION THEREOF |
US4732755A (en) * | 1983-01-17 | 1988-03-22 | University Of Health Sciences/The Chicago Medical School | Skin burn treatment |
US4822349A (en) | 1984-04-25 | 1989-04-18 | Hursey Francis X | Method of treating wounds |
JPS6270318A (en) * | 1985-09-25 | 1987-03-31 | Nippon Kayaku Co Ltd | Hemostatic and wound-protecting agent |
JPS63220876A (en) * | 1987-03-10 | 1988-09-14 | 日本曹達株式会社 | Wound protecting agent |
US5457093A (en) * | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
US4920158A (en) * | 1989-10-11 | 1990-04-24 | Medipro Sciences Limited | Hydrogel-forming wound dressing or skin coating material |
WO1992008449A1 (en) * | 1990-11-09 | 1992-05-29 | Teikoku Seiyaku Kabushiki Kaisha | Procaterol-containing plaster |
US5260066A (en) * | 1992-01-16 | 1993-11-09 | Srchem Incorporated | Cryogel bandage containing therapeutic agent |
US5459177A (en) * | 1993-03-09 | 1995-10-17 | Sun Medical Co., Ltd. | Adhesive for soft tissue and kit thereof |
US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
US5578661A (en) * | 1994-03-31 | 1996-11-26 | Nepera, Inc. | Gel forming system for use as wound dressings |
US5891074A (en) * | 1996-08-22 | 1999-04-06 | Avitar, Inc. | Pressure wound dressing |
US6706690B2 (en) * | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
CA2244017A1 (en) | 1998-07-28 | 2000-01-28 | Stephane Tetreault | Moisture-curable adhesive suture strip |
US6211296B1 (en) * | 1998-11-05 | 2001-04-03 | The B. F. Goodrich Company | Hydrogels containing substances |
US6060461A (en) | 1999-02-08 | 2000-05-09 | Drake; James Franklin | Topically applied clotting material |
US6531500B2 (en) * | 1999-07-23 | 2003-03-11 | Alwyn Company, Inc. | Methods for treatment of inflammatory diseases |
IL133473A0 (en) * | 1999-12-12 | 2001-04-30 | Avenir R & B Medical Technolog | Bactericidal haemostatic preparations for local use and the methods of their production and conservation |
US6187347B1 (en) | 2000-02-09 | 2001-02-13 | Ecosafe, Llc. | Composition for arresting the flow of blood and method |
US6399092B1 (en) * | 2000-12-27 | 2002-06-04 | Healthpoint, Ltd. | Anhydrous, hydrophilic absorbent wound dressing (tube) with antimicrobials or other pharmaceutically active agents |
-
2002
- 2002-06-20 AU AU2002350088A patent/AU2002350088A1/en not_active Abandoned
- 2002-06-20 CA CA2449436A patent/CA2449436C/en not_active Expired - Fee Related
- 2002-06-20 EP EP02780883A patent/EP1408902A4/en not_active Withdrawn
- 2002-06-20 IL IL15915602A patent/IL159156A0/en unknown
- 2002-06-20 US US10/178,448 patent/US7303759B2/en not_active Expired - Fee Related
- 2002-06-20 WO PCT/US2002/019554 patent/WO2003000155A2/en not_active Application Discontinuation
-
2003
- 2003-12-02 IL IL159156A patent/IL159156A/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133326A (en) * | 1994-08-31 | 2000-10-17 | Pfizer Inc | Compositions and methods for decreasing sebum production |
Non-Patent Citations (1)
Title |
---|
See also references of EP1408902A2 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003063922A1 (en) * | 2002-01-31 | 2003-08-07 | Aesculap Ag & Co. Kg | Haemostatic agent containing polyvinyl alcohol and provision of the same for medical use |
WO2008102150A2 (en) * | 2007-02-21 | 2008-08-28 | Pharmacure Health Care Ab | Composition for combating epistaxis |
WO2008102150A3 (en) * | 2007-02-21 | 2009-04-30 | Pharmacure Health Care Ab | Composition for combating epistaxis |
JP2010519285A (en) * | 2007-02-21 | 2010-06-03 | ファーマキュア ヘルス ケア エービー | Composition for combating nosebleeds |
AU2008217608B2 (en) * | 2007-02-21 | 2013-01-10 | Pharmacure Health Care Ab | Composition for combating epistaxis |
RU2473327C2 (en) * | 2007-02-21 | 2013-01-27 | Фармакьюэ Хелс Кеа Аб | Composition for fighting nosebleed |
CN101677940B (en) * | 2007-02-21 | 2014-02-19 | 法麻丘尔保健股份公司 | Composition for combating epistaxis |
US9138406B2 (en) | 2007-02-21 | 2015-09-22 | Pharmacure Health Care Ab | Composition for combating epistaxis |
EP2145617A1 (en) * | 2008-04-04 | 2010-01-20 | Ludzker, Benjamin | Gel formulation |
GB2488915B (en) * | 2011-03-11 | 2020-09-30 | Medtrade Products Ltd | Haemostatic material |
Also Published As
Publication number | Publication date |
---|---|
IL159156A (en) | 2010-11-30 |
IL159156A0 (en) | 2004-06-01 |
AU2002350088A1 (en) | 2003-01-08 |
EP1408902A2 (en) | 2004-04-21 |
US7303759B2 (en) | 2007-12-04 |
US20030008011A1 (en) | 2003-01-09 |
EP1408902A4 (en) | 2008-02-13 |
CA2449436C (en) | 2012-05-01 |
WO2003000155A3 (en) | 2003-07-03 |
CA2449436A1 (en) | 2003-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7303759B2 (en) | Compositions and methods for reducing blood and fluid loss from open wounds | |
JP7013336B2 (en) | In situ crosslinkable polymer compositions and methods thereof | |
Tompeck et al. | A comprehensive review of topical hemostatic agents: The good, the bad, and the novel | |
EP0356060B1 (en) | Wound filling compositions | |
JP2617260B2 (en) | Gel composition for wound treatment | |
US8409629B2 (en) | Hemostatic agent composition and method of delivery | |
JP4436994B2 (en) | Hemostatic agent, blood coagulant application method, blood coagulant base | |
AU2007313408B2 (en) | Formation of medically useful gels comprising microporous particles and methods of use | |
US20070255238A1 (en) | Hemostatic Polymer Useful for Rapid Blood Coagulation and Hemostasis | |
US20020197302A1 (en) | Hemostatic polymer useful for rapid blood coagulation and hemostasis | |
JP2017527416A (en) | Biocompatible hemostatic product and method for producing the same | |
KR20070100733A (en) | Agents for controlling biological fluids and methods of use thereof | |
US20230355835A1 (en) | Polymeric compositions, delivery devices, and methods | |
CN109689069A (en) | Wound covering object and its production method with anastalsis | |
JP2023516514A (en) | Medical adhesive, its preparation method, and its use | |
ES2902773T3 (en) | Polymeric Compositions, Delivery Devices, and Methods | |
KR101045030B1 (en) | Patch drug including the cross-linked drug-free hydrogel layer by irradiation | |
AU2008289571A1 (en) | Hemostatic agent composition and method of delivery | |
MX2007007072A (en) | Agents for controlling biological fluids and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 159156 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2449436 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002780883 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002780883 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |